Showing 34,862 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

HIV treatment

Emtricitabine/tenofovir disoproxil fumarate Factsheet

About HIV
September 2021
HIV treatment

Lamivudine/zidovudine Factsheet

About HIV
September 2021
HIV treatment

Etravirine Factsheet

About HIV
September 2021
HIV treatment

Atazanavir Detailed information

About HIV
September 2021
HIV treatment

Zidovudine Detailed information

About HIV
September 2021
HIV treatment

Zidovudine Factsheet

About HIV
September 2021
Coronavirus

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Editor's pick
University of Oxford
22 September 2021
Infant feeding

Parents Living With HIV Need Non-Judgmental Conversations Around Infant Feeding

Editor's pick
TheBodyPro
22 September 2021
Government, leadership & policy

England: HIV charities urge Ministers to fund end of new cases of HIV by 2030

Editor's pick
Terrence Higgins Trust
22 September 2021
Bad science & bogus treatments

Dear Governor Kemp: There Is No AIDS Vaccine

Editor's pick
POZ
22 September 2021
Pregnancy and vertical transmission

Antiretroviral Therapy for HIV Not Associated with Higher Risk for Preterm Birth

Editor's pick
Contagion Live
22 September 2021
Finance & funding

UK’s aid cuts are jeopardising progress in HIV response & hitting marginalised communities the hardest

Editor's pick
All Party Parliamentary Group on HIV/AIDS
22 September 2021
Global health initiatives

John Nkengasong, of the Africa C.D.C., Will Lead PEPFAR

Editor's pick
New York Times
22 September 2021
Injectable & long-acting HIV treatment

Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

Editor's pick
GlobeNewswire
22 September 2021
PrEP programmes & uptake

Don’t Underestimate the Benefit of HIV PrEP for Trans Women

Editor's pick
POZ
22 September 2021
HIV treatment

Ritonavir Factsheet

About HIV
September 2021
Sex workers

Successful PrEP interventions in marginalised communities: the Ashodaya PrEP Project

News
22 September 2021

aidsmap news: One dose of TAF every three days gets more drug into cells than a daily dose of TDF, 21 September 2021

September 2021
Kidney problems

People over 50 years old or with existing kidney dysfunction are more likely to get kidney damage when using tenofovir disoproxil-based PrEP

News
21 September 2021
Coronavirus

Children dying of Covid-19 in South Africa often also have HIV

Editor's pick
Business Day
20 September 2021
PrEP programmes & uptake

US: States Late to Adopt PrEP Risk Falling Further Behind

Editor's pick
American Journal of Managed Care
20 September 2021
Men who have sex with men (MSM)

Conversion therapy thrives globally as bans gather pace

Editor's pick
Thomson Reuters Foundation
20 September 2021
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Editor's pick
GlobeNewswire
20 September 2021
Access to healthcare

Unitaid at 15

Editor's pick
The Lancet (free registration required)
17 September 2021